Exonbio is committed to developing best-in-class in-vitro diagnostics antibodies to help alleviate the global burden of infectious diseases.
Negative-sense, non-segmented single-stranded linear RNA genome about 18-19 kb in size
Lancet-shaped, gram-positive, facultative anaerobic bacteria with more than 100 known serotypes
Eight single RNA segments with two major glycoproteins hemagglutinin and neuraminidase
Aerobic, non-motile, gram-positive, and non-spore-forming rod-shaped bacillus
Exonbio provides customers access to SPIN® platform with streamlined procedures for immunizations, screening, characterization, sequencing, purification, and recombinant production.
Patented SPIN® Technology
High-throughput screening has enabled interrogation of the natural antibody repertoire. Our proprietary Single Plasma Cell Interrogation (SPIN®) platform uses microfluidic technology to isolate antigen-specific plasma cells and single-cell technology to analyze native paired antibody genes.
High affinity: High affinity antibodies are selected owing to the isolation of the terminal differentiated plasma cells
Broad spectrum of epitope coverage: Unique properties of the rabbit immune system allows to obtain antibodies against a broad spectrum of epitopes for a single antigen